Trial Profile
Risk factors for bleeding during treatment with dabigatran or rivaroxaban in patients with atrial fibrillation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Oct 2015
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary) ; Rivaroxaban (Primary)
- Indications Stroke
- Focus Adverse reactions
- 30 Oct 2015 New trial record
- 02 Sep 2015 Results presented at ESC Congress 2015: Annual Congress of the European Society of Cardiology.